Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Пролонгированная контрацепция. Современные возможности, эффективность, перспективы (обзор литературы)
Прилепская В.Н., Хлебкова Ю.С. Пролонгированная контрацепция. Современные возможности, эффективность, перспективы (обзор литературы). Гинекология. 2016; 18 (1): 88–91.
________________________________________________
Prilepskaya V.N., Chernysheva E.S., Khlebkova Yu.S. Prolonged contraception. Modern possibilities, efficiency and prospects (literature review). Gynecology. 2016; 18 (1): 88–91.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Во всем мире гормональная контрацепция – популярный метод профилактики абортов. Разработаны различные режимы применения контрацептивных препаратов. Пролонгированный режим применения позволяет использовать эти лекарственные средства не только с целью контрацепции, но и для лечения и профилактики ряда гинекологических заболеваний. Одна из значимых проблем всех режимов применения комбинированных гормональных контрацептивов – вероятность пропуска приема таблеток. Доказано, что сам факт пропуска или позднего их приема может негативно влиять на эмоциональную составляющую жизни женщины. В настоящее время зарегистрирован новый режим приема препарата, содержащего дроспиренон (ДРСП) и этинилэстрадиол – ЭЭ (Джес®): 3 мг ДРСП+0,02 мг ЭЭ – 30 таблеток во флекс-картридже с прибором Клик (Clyk) для дозирования таблеток. Продемонстрировано, что гибкий пролонгированный режим обеспечивает надежность контрацепции, меньшее количество дней менструального кровотечения в сравнении с традиционным режимом, доказанную безопасность, облегчение течения заболеваний, ассоциированных с менструальным циклом, а дозатор Клик (Clyk) – простое и понятное в использовании инновационное устройство, помогающее повысить комплаентность и сократить количество нарушений режима приема.
Ключевые слова: гормональная контрацепция, пролонгированный режим применения, Джес во флекс-картридже и дозатор таблеток Клик (Clyk).
Ключевые слова: гормональная контрацепция, пролонгированный режим применения, Джес во флекс-картридже и дозатор таблеток Клик (Clyk).
________________________________________________
In modern world, hormonal contraception is a popular method of preventing abortions. Various modes of use of contraceptive drugs are developed. Prolonged application mode allows these drugs to be used not only for the purpose of contraception and the treatment, but also for prevention of a number of gynecological diseases. One of the significant problems of all modes of use of combined hormonal contraceptives is the probability of missed tablets. It is proved that the fact of missing or late they receive may be affected by the emotional component of a woman's life. Currently, the new regime of the drug containing drospirenone (DRSP) and ethinylestradiol – EE (Yaz®):
3 mg DRSP + 0.02 mg EE – 30 tablets of flex-cartridge device Click for dispensing tablets exists. It has been demonstrated that the flexible prolonged mode provides contraceptive reliability, fewer days of menstrual bleeding compared to traditional mode, proven security, alleviation of diseases associated with the menstrual cycle, and the Click dispenser is a simple and intuitive to use innovative device that helps improve compliance and reduce the number of violations of the receive mode.
Key words: hormonal contraception, the use of long-acting mode, Yaz Flex and Clyk.
Полный текст
Список литературы
1. Прилепская В.Н. Пролонгированная контрацепция – новый подход к решению женских проблем. Гинекология. 2005; 7 (4): 224–26. / Prilepskaya V.N. Prolongirovannaia kontratseptsiia – novyi podkhod k resheniiu zhenskikh problem. Gynecology. 2005; 7 (4): 224–26. [in Russian]
2. Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291–4.
3. ARHP/NPWH. Obstacles to using extended contraceptive regimens. Clin Proc 2003; April: 1–2.
4. Association of Reproductive Health Professionals. Choosing when to menstruate: the role of extended contraception. Retrieved April 21, 2004 from http://arhphoru/healthcareprovidcrs/visitiimfacultvprograms/ extended national surver, dm: 2002.
5. Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; Suppl. 12: S35–43.
6. Wiegratz Inka and Herbert Kuhl/Drugs 2004; 64 (21).
7. Wiegratz L, Hummel HH, Zimmermann T et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42.
8. Marshall LM, Spiegelman D, Goldman МВ еt al. А prospective study of reproductive factors and oral contraceptive use in relation оn the risk оf uterine leiomyomata. Fertil Steril 1998; 70: 432–9.
9. Friedman AJ, Thomas РР. Does low -dose combination оrаl contraceptive use affect uterine size оf menstrual flow in premenopausal women with leiomyomata. Obstet Gуnесоl 1995; 85: 631–5.
10. Ruchhoft Е, Elkind-Hirsch КЕ, Malinak R. Pituitary function is altered during the same cycle in women with polycystic оуагу syndrome treated with continuous оf cyclic оrаl contraceptives оf а gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60.
11. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18–30 years influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9.
12. Spona J, Elstein M, Heichtinger W et al. Contraception 2000.
13. Svemdottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13.
14. Sulak P, Scow RD, Precce C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
15. Stanford JL. Brinton LA, Berman ML et al. Oral contraceptives and endometrial cancer, do other risk factors modify the association? Int J Cancer 1993; 54: 243–8.
16. Blanchard K. Life without menstruation. Obstet Gynecol 2003: 5; 34–7.
17. Klipping C et al. J Fam Plann Reprod Health Care 2012; 38: 73–83.
18. Инструкция по эксплуатации на медицинское изделие. Устройство Клик (Clyk) для дозированной выдачи перорального контрацептивного препарата Джес®. / Instruktsiia po ekspluatatsii na meditsinskoe izdelie. Ustroistvo Klik (Clyk) dlia dozirovannoi vydachi peroral'nogo kontratseptivnogo preparata Dzhes®. [in Russian]
19. Wiegratz I et al. Efficacy, bleeding and tolerability of ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen supported by a tablet dispenser. Poster presented at ESG, Brussels 2013.
20. Klipping C, Duijkers I, Fortier MP et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73–83.
21. Klipping C, Duijkers I, Fortier MP et al. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012; 38: 84–93.
2. Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291–4.
3. ARHP/NPWH. Obstacles to using extended contraceptive regimens. Clin Proc 2003; April: 1–2.
4. Association of Reproductive Health Professionals. Choosing when to menstruate: the role of extended contraception. Retrieved April 21, 2004 from http://arhphoru/healthcareprovidcrs/visitiimfacultvprograms/ extended national surver, dm: 2002.
5. Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; Suppl. 12: S35–43.
6. Wiegratz Inka and Herbert Kuhl/Drugs 2004; 64 (21).
7. Wiegratz L, Hummel HH, Zimmermann T et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42.
8. Marshall LM, Spiegelman D, Goldman МВ еt al. А prospective study of reproductive factors and oral contraceptive use in relation оn the risk оf uterine leiomyomata. Fertil Steril 1998; 70: 432–9.
9. Friedman AJ, Thomas РР. Does low -dose combination оrаl contraceptive use affect uterine size оf menstrual flow in premenopausal women with leiomyomata. Obstet Gуnесоl 1995; 85: 631–5.
10. Ruchhoft Е, Elkind-Hirsch КЕ, Malinak R. Pituitary function is altered during the same cycle in women with polycystic оуагу syndrome treated with continuous оf cyclic оrаl contraceptives оf а gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60.
11. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18–30 years influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9.
12. Spona J, Elstein M, Heichtinger W et al. Contraception 2000.
13. Svemdottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13.
14. Sulak P, Scow RD, Precce C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
15. Stanford JL. Brinton LA, Berman ML et al. Oral contraceptives and endometrial cancer, do other risk factors modify the association? Int J Cancer 1993; 54: 243–8.
16. Blanchard K. Life without menstruation. Obstet Gynecol 2003: 5; 34–7.
17. Klipping C et al. J Fam Plann Reprod Health Care 2012; 38: 73–83.
18. Инструкция по эксплуатации на медицинское изделие. Устройство Клик (Clyk) для дозированной выдачи перорального контрацептивного препарата Джес®. / Instruktsiia po ekspluatatsii na meditsinskoe izdelie. Ustroistvo Klik (Clyk) dlia dozirovannoi vydachi peroral'nogo kontratseptivnogo preparata Dzhes®. [in Russian]
19. Wiegratz I et al. Efficacy, bleeding and tolerability of ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen supported by a tablet dispenser. Poster presented at ESG, Brussels 2013.
20. Klipping C, Duijkers I, Fortier MP et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73–83.
21. Klipping C, Duijkers I, Fortier MP et al. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012; 38: 84–93.
________________________________________________
1. Prilepskaya V.N. Prolongirovannaia kontratseptsiia – novyi podkhod k resheniiu zhenskikh problem. Gynecology. 2005; 7 (4): 224–26. [in Russian]
2. Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291–4.
3. ARHP/NPWH. Obstacles to using extended contraceptive regimens. Clin Proc 2003; April: 1–2.
4. Association of Reproductive Health Professionals. Choosing when to menstruate: the role of extended contraception. Retrieved April 21, 2004 from http://arhphoru/healthcareprovidcrs/visitiimfacultvprograms/ extended national surver, dm: 2002.
5. Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; Suppl. 12: S35–43.
6. Wiegratz Inka and Herbert Kuhl/Drugs 2004; 64 (21).
7. Wiegratz L, Hummel HH, Zimmermann T et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42.
8. Marshall LM, Spiegelman D, Goldman МВ еt al. А prospective study of reproductive factors and oral contraceptive use in relation оn the risk оf uterine leiomyomata. Fertil Steril 1998; 70: 432–9.
9. Friedman AJ, Thomas РР. Does low -dose combination оrаl contraceptive use affect uterine size оf menstrual flow in premenopausal women with leiomyomata. Obstet Gуnесоl 1995; 85: 631–5.
10. Ruchhoft Е, Elkind-Hirsch КЕ, Malinak R. Pituitary function is altered during the same cycle in women with polycystic оуагу syndrome treated with continuous оf cyclic оrаl contraceptives оf а gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60.
11. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18–30 years influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9.
12. Spona J, Elstein M, Heichtinger W et al. Contraception 2000.
13. Svemdottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13.
14. Sulak P, Scow RD, Precce C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
15. Stanford JL. Brinton LA, Berman ML et al. Oral contraceptives and endometrial cancer, do other risk factors modify the association? Int J Cancer 1993; 54: 243–8.
16. Blanchard K. Life without menstruation. Obstet Gynecol 2003: 5; 34–7.
17. Klipping C et al. J Fam Plann Reprod Health Care 2012; 38: 73–83.
18. Instruktsiia po ekspluatatsii na meditsinskoe izdelie. Ustroistvo Klik (Clyk) dlia dozirovannoi vydachi peroral'nogo kontratseptivnogo preparata Dzhes®. [in Russian]
19. Wiegratz I et al. Efficacy, bleeding and tolerability of ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen supported by a tablet dispenser. Poster presented at ESG, Brussels 2013.
20. Klipping C, Duijkers I, Fortier MP et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73–83.
21. Klipping C, Duijkers I, Fortier MP et al. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012; 38: 84–93.
Авторы
В.Н.Прилепская*, Ю.С.Хлебкова
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*VPrilepskaya@mail.ru
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*VPrilepskaya@mail.ru
________________________________________________
V.N.Prilepskaya*, Yu.S.Khlebkova
V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*VPrilepskaya@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.